About this Research Topic
Retroperitoneal sarcomas (RPS) account for 0.15% of all malignancies and approximately 15% of soft tissue sarcoma. Before progressing to a large volume and invading adjacent organs, RPS is difficult to detect due to a lack of symptoms. Because of the relative rarity and biological heterogeneity within RPS, the underlying complexity and diversity have impeded the development of robust disease site-specific or histotype-specific evidence to guide clinical management. Complete surgical resection remains the cornerstone of treatment for RPS, while the majority of them suffer a local recurrence within 5 years. The benefit of neo-adjuvant and adjuvant therapy seems to still struggle, with conflicting results in multiple randomized trials.
Therefore, comprehensive treatment strategies with surgery as the core are still of great importance, including the following aspects: (1) Surgical techniques, risk control, and perioperative management aimed at improving surgical resection rates; (2) Research status, challenges, and directions of neoadjuvant therapy for retroperitoneal sarcoma; (3) Difficulties in implementing histological type oriented surgical strategies; (4) Value of palliative surgery and tumor reduction surgery
Retroperitoneal sarcoma is a mesenchymal tumor with strong heterogeneity. This Research Topic mainly explores how to improve the completion rate of resection by integrating insights from various major sarcoma institutions, proposing a comprehensive treatment strategy centered on surgery. It mainly explores the indications for simple surgery and expanded resection surgery, the changes in treatment methods brought by adjuvant therapy and neoadjuvant therapy, the feasibility of treatment plans guided by pathological types, the challenges posed by tumor invasion of blood vessels, and the treatment direction for patients who cannot undergo surgical resection.
Specifically, submissions addressing the following subtopics are highly welcome.
1. Novel strategies for improving the complete surgical resection rate in retroperitoneal sarcoma.
2. Selection criteria for palliative medical treatment or surgical resection in retroperitoneal sarcoma.
3. Application standards for simple surgery and extended resection surgery in retroperitoneal sarcoma.
4. The difference in efficacy between simple adjuvant therapy and adjuvant therapy combined surgery in retroperitoneal sarcoma.
5. Current status, challenges, and directions of drug therapy for retroperitoneal sarcoma.
6. Surgical management strategies for retroperitoneal sarcoma involving vascular invasion.
7. Postoperative quality of life assessment in retroperitoneal sarcoma.
8. Relationship between histological types and surgical methods in retroperitoneal sarcoma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Therefore, comprehensive treatment strategies with surgery as the core are still of great importance, including the following aspects: (1) Surgical techniques, risk control, and perioperative management aimed at improving surgical resection rates; (2) Research status, challenges, and directions of neoadjuvant therapy for retroperitoneal sarcoma; (3) Difficulties in implementing histological type oriented surgical strategies; (4) Value of palliative surgery and tumor reduction surgery
Retroperitoneal sarcoma is a mesenchymal tumor with strong heterogeneity. This Research Topic mainly explores how to improve the completion rate of resection by integrating insights from various major sarcoma institutions, proposing a comprehensive treatment strategy centered on surgery. It mainly explores the indications for simple surgery and expanded resection surgery, the changes in treatment methods brought by adjuvant therapy and neoadjuvant therapy, the feasibility of treatment plans guided by pathological types, the challenges posed by tumor invasion of blood vessels, and the treatment direction for patients who cannot undergo surgical resection.
Specifically, submissions addressing the following subtopics are highly welcome.
1. Novel strategies for improving the complete surgical resection rate in retroperitoneal sarcoma.
2. Selection criteria for palliative medical treatment or surgical resection in retroperitoneal sarcoma.
3. Application standards for simple surgery and extended resection surgery in retroperitoneal sarcoma.
4. The difference in efficacy between simple adjuvant therapy and adjuvant therapy combined surgery in retroperitoneal sarcoma.
5. Current status, challenges, and directions of drug therapy for retroperitoneal sarcoma.
6. Surgical management strategies for retroperitoneal sarcoma involving vascular invasion.
7. Postoperative quality of life assessment in retroperitoneal sarcoma.
8. Relationship between histological types and surgical methods in retroperitoneal sarcoma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: sarcoma, soft tissue sarcoma, retroperitoneal sarcoma, surgery
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
